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Abstract 
Thrombotic thrombocytopenic purpura (TTP) is characterized by a syndrome of 
thrombotic microangiopathy (TMA), with severe consumption thrombocytopenia, 
microangiopathic haemolytic anaemia (MAHA), and a variable degree of ischemic end 
organ damage. Acquired TTP is due to an ADAMTS13 deficiency, a metalloprotease 
that cleaves the von Willebrand (VWB) factor. TTP patients exhibit uncleaved ultra-
large VWF multimers that bind to platelets in high sheer environments. Organ 
ischaemia occurs then as a consequence of microvascular occlusion. The disease carries 
a 90% mortality rate if left untreated. Misdiagnosis can affect outcomes Initial 
management focuses on ruling out other potential causes of TMA (shigatoxin-related 
haemolytic and uremic syndrome (HUS), complement mediated HUS, or secondary 
TMA syndromes). Despite the lack of consensual definition of severe TTP, a large 
number of TTP patients are managed in the ICU for either severe organ failure, or to 
ease management and optimal monitoring. Early plasma exchange (PEX) and 
corticosteroids significantly reduced mortality. Sudden death can occur anytime within 
the first days of treatment initiation, mostly from coronary occlusion or cardiogenic 
shock. Rituximab has been advocated at the earliest phase of severe TTP, along with 
the just released caplacizumab. In this expert statement written by a group of ICU 
specialists used to manage patients with TMA syndromes, we sought to inform and 
guide clinical management of critically ill patients with TTP. Participating experts have 
agreed and graded items related to diagnostic workup, assessment of patient’s severity, 
standard of care for TTP patients and for second line therapy in patients who are 
unresponsive to initial treatment. Finally, unanswered questions are raised, leaving a 
research agenda on the critical care aspects of TTP.  
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1. Introduction (574) 
Acquired thrombotic thrombocytopenic purpura (TTP) is a haematological and 
critical care emergency, with a mortality of 90% if left untreated. The disease is 
characterized by a syndrome of thrombotic microangiopathy (TMA), with severe 
consumption thrombocytopenia, microangiopathic haemolytic anaemia (MAHA), and 
a variable degree of ischemic end organ damage. Early plasma exchange (PEX) and 
corticosteroids significantly reduced the mortality to about 15% 1,2. Acquired TTP is 
due to a deficiency of the von Willebrand factor (VWF) cleaving serine 
metalloprotease, called ADAMTS13 (A Disintegrin And Metalloprotease with a 
ThromboSpondin type 1 motif, member 13) 3–5. Anti-ADAMTS13 autoantibodies that 
either inhibit ADAMTS13 proteolytic activity (neutralizing antibodies), or enhance 
ADAMTS13 clearance (non-neutralizing antibodies) contribute to the pathogenesis of 
acquired TTP 6,7. Organ ischaemia occurs as a consequence of MAHA and 
microvascular occlusion from microthrombi resulting from uncleaved ultra-large VWF 
multimers that bind to platelets in high sheer environments 8.  
The diagnosis of TTP is based on clinical and biological findings. TTP 
prevalence is 10-15 cases per million people, with a sex ratio of 2 women for a man, 
and a peak incidence of disease occurring before the age of 50 years9. In adults, acquired 
TMA syndrome and signs of organ ischemia are highly suggestive of TTP. Initial 
management focuses on ruling out other potential causes of TMA, namely, shigatoxin-
related haemolytic and uremic syndrome (HUS), complement mediated HUS, or 
secondary TMA syndromes. Once ADAMTS13 activity is found undetectable, with or 
without anti-ADAMTS13 antibody, TTP diagnosis is then established 4,10–12. 
Noteworthy, sampling for ADAMTS13 activity should be collected immediately and 
prior to any plasma therapy, but clinicians should start PEX without waiting for 
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ADAMTS13 results. Misdiagnosis can affect outcomes and often leads to unnecessary 
and excessive use of hospital resources13. Along the same line, delay in implementing 
PEX has been associated with increased mortality14,15. Hence, clinicians should 
maintain a high level of suspicion towards the diagnosis of TTP. Moreover, in the 
sickest TTP patients with severe organ dysfunction, early PEX correlates with faster 
remission 16. 
There is no consensual definition of severe TTP. Yet, a large number of TTP 
patients are managed in the ICU11,17 for either severe organ failure, or because the ICU 
is the only place in the hospital where a PEX can be performed, a central line be 
inserted, or a careful monitoring offered at any time. Indeed, sudden death can occur 
anytime within the first days of treatment initiation, mostly from coronary occlusion or 
cardiogenic shock 18. In a retrospective study comparing TMA patients who died with 
TMA survivors, lack of PEX implementation and cardiac involvement were the leading 
causes of death 14.  
Statements or consensus guidelines for the management of TTP patients have 
previously been published10,19–21. In this expert statement written by a group of ICU 
specialists used to manage patients with TMA syndromes, we sought to inform and 
guide clinical management of critically ill patients with TTP, with a particular focus on 
patients with severe organ dysfunction and high risk of sudden death. Moreover, the 
recent release of caplacizumab, an anti-VWF recently approved in Europe and by the 
US Food and Drug Administration, motivated our group to review and clarify the basic 
standard of care, since the optimal benefits of this new treatment will be gauged against 
a background of high-quality standardized care. Participating experts have agreed and 
graded items related to diagnostic workup, assessment of patient’s severity, standard of 
care for TTP patients and for second line therapy in patients who are unresponsive to 
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initial treatment. Finally, unanswered questions are raised, leaving a research agenda 
on the critical care aspects of TTP to be hopefully conducted in the next five years. 
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2. Search strategy  
A literature search (time between 1978 and 2018) was conducted using the National 
Library of Medicine database (PubMed) and the Cochrane database using the following 
search terms: “TTP”, “Thrombotic thrombocytopenic purpura” or “ADAMTS13 
deficiency” with search filters of “humans” and “English language”. These terms were 
combined with additional search terms: “Clinical prediction score”, “prediction”, 
“score” or “diagnosis” when identifying publications pertaining to definitions and 
scoring for severe TTP; and “ICU”, “intensive care”, “critical care” or “critical illness” 
when searching for publications related to TTP in ICU. Additional relevant articles 
were also included from Internet searches using the same search terms. 
Formulation of the guidelines was conducted according to the Grade of 
Recommendation Assessment, Development and Evaluation methodology 22,23. A 
strong agreement was reached on all the recommendations. The guidelines were 
focused on four 4 areas: diagnostic workup, severity assessment, standard of care and 
second line therapy.  
 
 
8 
 
3. TTP in the ICU 
We identified six studies that reported on critically ill patients with TTP (Table 
2).15,16,39–42 These populations differed in terms of severity of illness, organ support and 
mortality, which may be attributable to variation in admission policies across centres. 
Neurological signs, renal impairment and cardiac abnormalities were commonly 
observed. However, life sustaining therapies were variably applied with ventilator 
support reported in 30-50% of patients, and renal replacement therapy in 0-19%. 
Hospital mortality was reported in all studies and ranged from 4.3% in the study by 
Zafrani et al.39 to 34.9% in the study by Pene et al.,15 where patients were sicker than 
in other ICU studies.  
 
Why TTP patients should be managed in the ICU? 
In many TTP cases, ICU care may be necessary because of severe organ 
failure12 or injury (table 5) such as coma, stroke, seizure, posterior reversible 
encephalopathy syndrome47,48, myocardial infarction, congestive heart failure49, 
arrhythmia,18 mesenteric ischemia, pancreatitis,50 or acute kidney injury39. Beyond 
severe organ dysfunction, critical care environment also offers close monitoring to 
patients at high risk of clinical deterioration, secures catheter placement in patients with 
profound thrombocytopenia, or facilitates urgent treatment with plasma exchange.45 
Indeed, TTP is a medical emergency that requires rapid recognition and specific 
treatment as soon as the diagnosis is suspected. At many hospitals, the ICU is the only 
place where central line placement and plasma exchange can be rapidly initiated with 
adequate patient’s monitoring. For other patients, TTP may not have been diagnosed 
initially and patients were already in the ICU with presumed alternate diagnosis such 
as sepsis51.  
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When TTP patients should be managed in the ICU? 
TTP patients should be managed in the ICU upon diagnostic recognition of 
TMA, to initiate plasma exchange14,40,41 and to support organ failure with mechanical 
ventilation, vasopressor support or renal replacement therapy.15,52 Refractory or 
relapsing TTP unresponsive to initial management should also be treated in ICU.40 ICU 
may also be needed in case of catheter related complications such as bleeding, infection 
or thrombosis, and in case of plasma transfusion reaction,53 or worsening neurologic 
abnormalities after plasma exchange.54 ICU discharge will depend on the response to 
treatment and resolution or organ failures. However, hospital facilities (availability of 
a step down or intermediate care unit), existence of an apheresis department, and 
hospital organization (monitoring facilities in the wards, availability of a rapid response 
team) should be taken into account when making the decision of ICU discharge.  
 
Which TTP patients should be managed in the ICU? 
All TTP patients should be managed initially in ICU.10,14,41,45 Admission to ICU 
may be elective (e.g. initiation of plasma exchange for a patient in whom diagnosis is 
strongly suspected or even made), urgent (to confirm the diagnosis and initiate 
treatment) or emergent (need for intubation and mechanical ventilation, hemodynamic 
support or renal replacement therapy). Special circumstances (e.g. pregnancy) are 
especially at risk and deserve ICU admission for optimal multidisciplinary 
management. Management should be performed preferably in a reference centre by a 
multidisciplinary team with experience in TTP for both ICU and long term 
managements.   
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4. TTP definitions and scoring 
 
TMA diagnosis is based on clinical findings, MAHA with schistocytes, 
peripheral thrombocytopenia and organ dysfunction8. 
In 1966, based on a review of 270 cases, Amarosi and Ultman proposed the 
following ”pentad” for the diagnosis of TTP24: fever, haemolytic anaemia, purpura or 
bleeding associated with thrombocytopenia, neurological signs, and renal disease 
presented with haematuria and/or proteinuria or elevated blood urea nitrogen. However, 
later studies found that patients diagnosed with TTP were commonly lacking one or 
more elements of the pentad.  
It has since become evident that measurement of ADAMTS13 activity is 
necessary to confirm the diagnosis of TTP4,6,7,12. However, ADAMTS13 analysis may 
not be immediately available to guide clinical management. As a consequence, almost 
every TMA syndrome in adults requires urgent plasma therapy, unless evidence for an 
alternate diagnosis can be quickly gathered (malignant hypertension, vitamin B12 
deficiency, metastatic cells in the bone marrow smear, scleroderma renal crisis, etc…).  
Attempts have been made to address this early diagnosis issue, and several 
scoring systems have been developed to predict severe ADAMTS13 deficiency and 
diagnosis of TTP (Table 1). However, if these scores are able to stratify patients for a 
higher likelihood of TTP, none of these can replace ADAMTS13 testing. Based on data 
from the French TMA Reference Centre, Coppo et al. proposed a simple scoring system 
based on three criteria to predict severe ADAMTS13 deficiency.27 They included a 
serum creatinine <200 μmol/L, platelet count <30 x 109/L and positive antinuclear 
antibody test; when all three criteria are present, the positive predictive value is 99% 
though the negative predictive value is only 39% suggesting that these criteria cannot 
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rule out ADAMTS13 deficiency.27 Moreover, antinuclear antibody testing may not be 
promptly available either. Bentley et al developed another score based on results from 
100 patients using five criteria: creatinine, platelets, D-dimer, reticulocytes and indirect 
bilirubin.28 This score has since been validated29 and can be useful at predicting disease 
when the score is >30, and in ruling out disease when <20, but intermediate scores are 
difficult to interpret and not discriminative. Finally, the PLASMIC scoring system, 
published in 2017, uses seven criteria: platelet count <30 x 109/L, haemolysis, no active 
cancer, no history of solid-organ or stem-cell transplant, mean corpuscular value <9 x 
10-14 L, INR <1.5 and creatinine <2mg/dL (177umol/L) with one point for each positive 
criterion.30 An independent external validation of the PLASMIC score was performed 
in a cohort of 112 patients with TMA: Area under the curve (AUC) was 0.94 (0.88-
0.98) and a score of 6 or 7 predicted severe ADAMTS-13 deficiency with a positive 
predictive value of 72%, a negative predictive value of 98%, a sensitivity of 90% and a 
specificity of 92%.31 Hence, until dedicated resources are made available to obtain 
reliable ADAMTS13 testing within a few hours, scoring systems will continue to be 
used to stratify patients, but clinicians should understand their limitations and reasons 
for not initiating plasma therapy within hours of ICU admission should rely on clear 
and undisputable alternate diagnoses.10  
If ADAMTS13 activity is detectable, typical HUS (positive shigatoxin on the 
rectal swab), complement-mediated-HUS) or secondary TMA syndromes45 should be 
considered.  
As plasma exchanges will remove a significant proportion of plasma proteins, 
including antibodies and substances bound to albumin [8, 9], they may alter the results 
of most plasma studies. The initial biological workup should best be retrieved before 
the onset of plasmatherapy. One study has shown that ADAMTS13 activity is usually, 
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but not always, still severely decreased in the first 3 days following the onset of PEX 
in patients with TTP. [10] 
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5. TTP and organ dysfunction  
TTP is a multisystem disorder. Organ dysfunction occurs as a consequence of 
widespread microvascular thrombosis (Figure 1). Thrombi occur at high density in the 
heart, brain and kidney causing transient or partial occlusion of vessels resulting in 
intermittent ischemia.8 Several registry-based studies have reported the common signs 
and symptoms of this condition that are presented in Tables 2 and 3, and in Figure 
2.9,27,32,33 Neurological impairment is common and proteiform, including headache, 
altered personality, reduced cognition, seizures, transient ischemic attacks and coma.9,32 
These signs and symptoms often fluctuate in presentation and severity, due to the 
formation and dissolution of thrombi in the cerebral microcirculation.8 When the 
coronary vessels are involved patients can experience acute myocardial infarction, 
arrhythmias, heart failure, cardiogenic shock, and troponin levels are often 
elevated.18,34,35 Abdominal pain can occur due to acute pancreatitis or to mesenteric 
ischemia with resulting diarrhoea .36 
Several studies have suggested that renal involvement is not a predominant 
feature of TTP (table 2).27,29,37,38 However, renal involvement may still occur due to 
either the TTP itself, haemolysis, blood pressure lability or drug-related renal toxicity. 
The study by Zafrani et al. reviewed all cases of TTP (with ADAMTS13 activity <10%) 
admitted to a single ICU over a twelve year period and described the rate of acute 
kidney injury (AKI).39 They found that AKI (defined based on KDIGO 2012) was 
common and affected 58.7% of patients. AKI was ascribed to TTP itself in 96.3% of 
patients, with potential kidney injuries being hypoperfusion (16.7%), acute tubular 
necrosis (7.4%), nephrotoxicity (9.3%), haemolysis-induced tubulopathy (33.3%) and 
autoimmune glomerulonephritis (14.8%). Among those patients with AKI, 42.6% had 
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chronic kidney disease at 6 months. This high rate of renal injury was also observed in 
several of the other papers published within the ICU setting (Table 2).9,15,16 
 
Recommendations for TTP diagnostic workup (table 7A) 
a) Experts suggest that all patients suspected of having TTP should undergo, at 
least, the following workup:  
• Full clinical screening for organ injury (neurologic, cardiac, renal, 
gastrointestinal). 
• Biological workup to diagnose TMA: Blood cell count and smear (reticulocytes 
and schistocytes). Biochemistry: LDH, haptoglobin, bilirubin, Direct Antiglobulin Test 
to rule out Evans syndrome, basic coagulation tests to rule out DIC, proteinuria, 
haematuria.  
• Biological workup to confirm TTP: Non-heparinised samples for ADAMTS13 
activity and anti-ADAMTS13 antibodies before TPE, alternative pathway of the 
complement system study, and PCR on rectal swab for shiga-toxin.  
• Minimal tests to assess organ involvement (troponin, ECG, renal function, 
lipase) and to identify possible associated conditions (auto-immunity markers, HIV 
serology, β-HCG, blood cultures). 
• Cross-matching before transfusion (blood group, hepatitis serologies). 
GRADE for a): Expert opinion, Agreement: Strong 
b) Blood samples should probably be obtained before starting plasma therapy. 
GRADE for b): 2+, Agreement: Strong 
c) Diagnostic workup should probably not delay TPE. 
GRADE for c): 2-, Agreement: Strong 
d) When ADAMTS13 activity cannot be easily or quickly measured, diagnostic 
scores (French score, Bentley score, PLASMIC score) should probably be used to 
assess whether ADAMTS13 is likely to be undetectable. 
GRADE: 2+, Agreement: Strong 
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6. Assessing TTP severity  
In acquired TTP, microvascular thrombosis translates into ischemic end organ 
damage so rapid and accurate diagnosis is crucial for survival.13 Schistocytes may be 
absent initially; this may distract and delay the diagnosis with severe consequences, 
especially since the first acute episode is usually more severe than recurrent episodes.55 
Platelet transfusions are often administered before the correct diagnosis has been made, 
and have been associated with clinical deterioration and increased relapse rate.56,57  
Urgent (within 4-6 hours of admission) plasma exchange therapy is vital for 
recovery and should be initiated in the ICU, as TTP patients have increased risk of 
adverse effects of plasma exchange therapy.58 Lack of response to plasma exchange 
therapy is associated with more severe complications, higher consumption of ICU 
resources, and increased mortality.40,59 In centres able to perform prompt diagnosis and 
treatment, mortality is as high as 10% overall,9,32 and among unresponsive patients, up 
to 30% die.40 Mortality is even higher when the diagnosis is missed or the treatment 
delayed.14,60 Therefore, it is crucial to identify patients at high risk of mortality or 
unresponsive disease early (Table 6), in order to be able to offer a more aggressive 
treatment regimen.10,61  
By 1987, Rose et al. had developed a “TTP Clinical Severity Score” based on 
serum creatinine, platelet count, haemoglobin level, and neurologic symptoms, in an 
attempt to risk stratify patients.25 In their study, higher scores were associated with 
worse outcome. However, this finding was not confirmed in further studies, probably 
due to the inclusion of patients with both TTP and HUS.26 
One of the most common reasons for death is cardiac ischemia18 and autopsy 
studies have found that widespread myocardial microthrombosis is ubiquitous in TTP 
patients.14,36,62 Furthermore, patients with cardiac involvement are more likely to be 
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unresponsive to treatment.40 Increased cardiac troponin level is associated with 
mortality34,63,64 even though most patients with increased cardiac troponin levels are 
asymptomatic.18,49 Benhamou et al. found that patients with a cardiac troponin I level 
of > 0.25 μg/L had more cardiac and cerebral involvement and high levels of troponin 
were also found in patients with stroke.34 Chest pain, ECG changes and troponin must 
be assessed routinely at presentation and on a regular basis throughout the course of the 
disease. Transthoracic echocardiography is part of the routine diagnostic workup in the 
ICU. Coronary angiography may be reserved to selected patients with risk factors and 
signs of acute coronary syndrome, its indication being discussed on a case by case basis 
along with a cardiologist. 
Cerebral involvement has been associated with worse outcome65 and symptoms 
of brain ischemia such as severe seizures and coma have been linked to severe 
ADAMTS13 deficiency.66 There are other factors associated with worse outcome, such 
as older age67,68 and a lactate dehydrogenase (LDH) increase ≥10 x normal value, 
although increased LDH level is probably related to severe multiorgan failure (Table 5 
and 6).65,68 Therefore, in stratifying for TTP severity, emphasis should be on measuring 
cardiac troponin levels and assessing cardiac and cerebral involvement (Figure 2).  
General ICU management applies to TTP patients. Namely, this includes early 
ICU admission, optimal ICU monitoring, increasing awareness that sudden 
deterioration is possible at any time, standard measures to preserve organs and correct 
metabolic disturbances. Upon initial management, careful clinical evaluation will 
assess disease severity. No specific data is available on the management of organ 
dysfunction in TTP patients (red cell transfusion thresholds, decision to intubate 
patients with coma or stupor, anti-epileptic prophylaxis, renal replacement therapy, 
extracorporeal life support, etc…).  
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In every adult patient with TMA, we advocate to pay specific attention to 
increased cardiac and neurologic risks 14,18,49. The disappearance of signs of haemolysis 
and the platelet count increase over 150G/L usually correlate with cardiac and 
neurological improvements10,94,95, allowing TPE tapering or stop. These markers may 
be used to decide when to discharge TTP patients from ICU. ICU discharge also 
depends on the availability of an apheresis unit in the hospital. Follow up should be 
made by a multidisciplinary team including TTP experts, haematologists, as well as 
ICU and organ specialists. 
 
Recommendations for assessment of TTP severity (table 7B) 
a) Organ dysfunction should probably be assessed routinely at presentation and 
throughout the course of TTP. 
GRADE: 2+, Agreement: Strong 
Experts do not provide guidance for the management of organ dysfunction in TTP 
patients.  
Not Graded 
b) Experts suggest that the presence of cardiac involvement (ie. chest pain, ECG 
and trans-thoracic echography changes, and troponin) must be assessed 
routinely at presentation and on a regular basis throughout the course of TTP.  
GRADE: Expert opinion, Agreement: Strong 
Older age, cerebral involvement and persistently high LDH may help identify TTP 
patients at increased risk of early death.  
GRADE: 2+, Agreement: Strong 
Experts suggest that all patients diagnosed with TTP must be initially admitted to an 
area of Critical Care in order to monitor and manage organ dysfunctions, and to 
provide urgent plasma exchange therapy.  
GRADE: Expert opinion, Agreement: Strong 
Experts suggest that ICU discharge be allowed when TPE can be tapered or stopped, 
when signs of haemolysis disappear and platelet count increases over 150G/L, which 
usually correlates with cardiac and neurological improvements. Patients can be 
discharged from the ICU earlier if there is a TPE unit in the hospital. 
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GRADE: Expert opinion, Agreement: Strong 
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7. TTP and pregnancy 
Pregnancy can be a precipitating cause of TTP and accounts for 2-8% of all TTP 
cases9,32. While hereditary TTP only accounts for 3-5% of TTP cases, an unusually high 
prevalence of hereditary TTP clustered in the obstetric population was reported. It can 
represent 25-60% of cases as hereditary TTP often manifests for the first time during 
pregnancy43,44. The presence of severe thrombocytopenia during pregnancy may pose 
a challenge to physicians given the wide differential diagnosis with many overlapping 
clinical features. Differentiating pregnancy-associated TTP from incidental causes is 
paramount to guide management. The differential diagnosis of thrombocytopenia with 
MAHA during pregnancy include ADAMTS13 deficiency (TTP), complement 
mediated thrombotic microangiopathy (aHUS), HELLP syndrome (microangiopathic 
haemolytic anaemia, elevated liver enzymes, low platelet count), and disseminated 
intravascular coagulopathy (DIC) (table 4). In TTP, intrauterine foetal death may occur 
due to placental infarction due to thrombus formation in the decidual arterioles. In those 
cases, the risks to the mother and foetus are minimized with prompt recognition and 
initiation of plasma therapy.  
We advocate for close collaboration and interaction between critical care 
specialists and TTP experts (haematologists, clinical immunologists, internists, and/or 
nephrologists). In this specific area of rare diseases, clinicians, biologists and 
researchers must align skills and knowledge to create a collective experience-based 
management that goes far beyond the acute care setting and will benefit present and 
future patients. Hence, multidisciplinary team is the best option to manage TTP.45 This 
should translate into improved clinical performances,46 and improved outcomes. In the 
setting of pregnancy, early involvement and communication between the intensivist, 
high-risk obstetric team and haematologists should be pursued to assist with diagnosis 
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and management. In TTP patients, there is no maternal indication for early delivery, 
only foetal indications, and the management is similar to the non-pregnant patients with 
TTP. When there is uncertainty regarding the diagnosis, while awaiting the 
ADAMTS13 activity results, plasma exchange should be initiated. Platelet transfusions 
should not be withheld in the setting of severe bleeding.  
GRADE: Expert opinion, Agreement: Strong 
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8. Therapeutic targets in TTP 
Even though first-line TTP therapy has been based on plasma exchange and 
steroids until recently, several TTP targets exist and could also be considered as first 
line therapies61 (Figure 3). This paragraph provides the rationale for the use of available 
treatments, whereas the next paragraph details the standard of care for first and further 
line therapy in TTP patients.  
  
Replacement therapy 
Therapeutic plasma exchange (TPE) that provides large amounts of functional 
ADAMTS13 via substitution with fresh frozen plasma, remains today the cornerstone 
in TTP treatment.12,69 It prevents excessive binding of ultralarge VWF multimers to 
platelets, with subsequent aggregation and microthrombi formation within the 
microvessels. Whether the technique effectively removes anti-ADAMTS13 
autoantibodies has not been properly assessed. Plasma infusion alone, although far less 
effective1,16,70, may be provided when expecting delayed initiation of TPE because of 
hospital organization or availability of an apheresis slot or a TPE machine1.  
Immunomodulation 
Given the autoimmune origin of acquired TTP in adults, there is a rationale for 
immunomodulation and a variety of treatment strategies exists. Corticosteroid 
treatment is recommended in the initial phase, together with TPE.10,19 A trial of 
corticosteroids in patients with TMA has even demonstrated that in selected cases, they 
induced prolonged clinical remission.2 However, this trial published in 1991 did not 
distinguish among the different clinical entities of TMA, particularly patients with 
STEC-HUS, aHUS or secondary TMA who do not require corticosteroid. Rituximab, a 
monoclonal antibody targeting CD20 on B cells, has shown to reduce the relapse rate 
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in refractory cases of TTP,  reduce the level of anti-ADAMTS13 antibody and  increase 
functional ADAMTS13 activity.71–79Furthermore, the benefits from several other 
immunosuppressive and cytostatic drugs in addition to PEX have been reported in 
smaller studies and case reports as salvage therapy, in refractory cases of TTP. These 
include vincristine (halting cell division), cyclosporine A (targeting T-cells effector 
functions), cyclophosphamide (alkylating agent), bortezomib (proteasome inhibitor), 
and complement (C5) inhibition by eculizumab80–88. Splenectomy should only be 
considered as salvage therapy in patients with severe TTP manifestations unresponsive 
to all other treatments83.  
Prevention of VWF binding to platelets 
N-acetylcysteine, by inhibiting platelets adherence to endothelial-anchored 
ultralarge vWF by reducing their size, has been used successfully in case reports89.  
In June 2018, the European Medicine Agency’s Committee for Medicinal 
Products for Human Use (CHMP) has recommended approval of caplacizumab in 
Europe for the treatment of adults experiencing an episode of acquired TTP. 
Caplacizumab has also been fast-tracked by the FDA. Marketing Authorisation 
Application for Caplacizumab has been approved for the treatment of acquired TTP in 
the US on February 6th 2019.  
Caplacizumab, an anti-VWF humanized single-variable-domain 
immunoglobulin (nanobody), inhibits the interaction between ultralarge VWF 
multimers and platelets by targeting VWF-1b, thereby preventing thrombi formation. 
Faster platelet count recovery and resolution of organ damage has been demonstrated 
in TTP patients receiving caplacizumab. In the phase 2 TITAN trial91, 75 TTP patients 
were randomly assigned to caplacizumab (10 mg daily) or placebo. There was a 
significant improvement in the primary endpoint (39% reduction in median time to 
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platelet count normalization) in the caplacizumab group. Fewer caplacizumab-treated 
patients had a major thromboembolic event, a TTP exacerbation, or died versus placebo 
(11.4% vs. 43.2%)91. More recently, in the double-blind, controlled HERCULES trial, 
145 patients were randomly assigned to either caplacizumab or placebo during plasma 
exchange and for 30 days thereafter17. The median time to normalization of the platelet 
count was shorter with caplacizumab than with placebo (2.69 days [1.89-2.83] vs. 2.88 
days [2.68-3.56]). Patients who received caplacizumab required less plasma exchange 
procedures and had a shorter hospitalization than those who received placebo. The 
percentage of patients with a composite of TTP-related death, recurrence of TTP or a 
thromboembolic event during the treatment period was lower with caplacizumab than 
with placebo (12% vs. 49%, P<0.001). Only 12% of the caplacizumab-treated patients 
underwent TTP recurrence at any time during the trial and none developed a refractory 
disease (vs. 38% and 4%, respectively). Mild to moderate bleedings were more 
common with caplacizumab as compared to placebo (54% vs. 38% in the TITAN trial 
and 65% vs. 48% in the HERCULES trial). Combining TITAN and HERCULES trials, 
TTP-related deaths were 0% (0/107) in the caplacizumab group versus 4.5% (5/110) in 
the placebo group. In June 2018, the European Medicines Agency’s Committee for 
Medicinal Products for Human Use has recommended approval of caplacizumab in 
Europe for the treatment of adults experiencing an episode of acquired TTP. 
Caplacizumab was approved on August 2018. Caplacizumab was also approved by the 
US Food and Drug Administration for the treatment of acquired TTP on 06 February 
2019. 
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9. Standard of care for treatment of severe TTP (table 7) 
Standardizing first-line management of patients with suspected TTP is a challenge10. 
TTP recognition, diagnostic workup, exclusion of differential diagnoses, and first-line 
patient management must not be delayed (figures 4 and 5).  
Standard of care for patients with severe TTP  
Whether the first line therapy should be limited to only PEX and corticosteroids, 
or should include early rituximab and caplacizumab in all ICU patients independently 
of the severity remains an unresolved issue. Treatment should not be delayed until the 
diagnostic workup for both TTP and differential diagnoses is complete (figure 2), with 
emphasis on obtaining a reliable test to ascertain ADAMTS13 blood level before any 
plasma therapy. The best way to preserve organ function is to implement early a high 
volume PEX1,16. We advocate that every critical care specialist should be able to 
manage a patient with TMA, diagnose TTP appropriately and promptly, evaluate TTP 
severity, and implement first line therapy within the first hours of ICU admission. In 
the following days after ICU admission, we also recommend that a TTP specialist be 
involved in patient’s management, irrespective of the severity, most particularly to 
provide an expert consult on the underlying condition, share advances in disease 
understanding and updated therapies and recommendations, prepare ICU discharge and 
inform patient about long term outcomes. According to patient’s severity and organ 
involvement, appropriate consults might also be called (i.e., cardiologists, neurologists, 
nephrologists, etc.). 
Therapeutic Plasma Exchange (TPE) is urgent and should be initiated within 4-
6 hours of TMA diagnosis (figures 4 and 5), as the risk of death is maximal before TPE 
onset14,15. TPE is superior to plasma infusions in terms of morbidity and mortality1,16. 
Plasma infusions should only be used when TPE is not immediately available, until the 
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patient is transferred to another centre. The experts suggest to perform one TPE per day 
with a dose of plasma of 60 ml/kg (1.5 x estimated plasma volume) until platelet count 
is above150G/L for ≥48 hours. TPE should be repeated every day until remission (see 
definition below). When no alternative is available, placement of a central venous 
catheter should be performed by an experienced operator, under ultrasound guidance, 
without platelet transfusions96. Indeed, platelets transfusion and medications that may 
induce microvascular injury (desmopressin, vasopressin, tranexamic acid, etc…) 
should be avoided, unless a life threatening haemorrhage occurs10. It should however 
be noted that despite profound thrombocytopenia, TTP is far more an ischemic than a 
haemorrhagic disease. Plasma availability should be checked with the blood bank, and 
all pre-transfusion requirements should be applied97.  
Initial immunosuppression includes methylprednisolone (1 mg/kg) or 
equivalent2,10,98 and may be given for 21 days. Corticosteroids may also reduce side 
effects often observed with PEX 99. In case of severe TTP, high dose pulse 
corticosteroids (e.g. 1 g of methylprednisolone) may be given daily for three 
consecutive days100 
Rituximab is used off-label in TTP, but is very effective to eradicate the 
autoantibodies72,73. Rituximab is given in patients with relapsing TTP 40,75,77,101. The 
slow onset of action, about 10-14 days, makes it unlikely to manage effectively TTP 
severity at the initial phase and prevent early deaths. However, it may prevent delayed 
exacerbations and relapses98. There are no studies comparing upfront (empirical) vs. 
individualized (ADAMTS13-based) use of rituximab. Scully et al. reported faster TTP 
remission with rituximab compared to historical controls,77 a finding confirmed by the 
French study group75. Despite the lack of a proper clinical trial in patients with severe 
TTP, rituximab may however be overall beneficial 73,75,77,78. We recommend that in 
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critically ill TTP patients, rituximab be used as a first line agent in all patients. Standard 
lymphoma doses should be used, but shorter regimen based on B-cell depletion may be 
considered as well 72,102. Some have suggested a twice weekly schedule administration 
of rituximab in acute TTP due to the removal of the molecule by PEX72. 
The experience of this group with caplacizumab is limited to the participation 
for some of its members into the two published RCTs17,90, or off label in temporary 
authorization programs. Thus, none of the members of this group has a large personal 
experience with caplacizumab given under real-life conditions. The current approved 
use of caplacizumab is for the treatment of adult patients with acquired TTP, in 
combination with PEX and immunosuppressive therapy.  We suggest that, in critically 
ill patients with severe TTP and high risk of thromboembolic events, exacerbations, 
relapse, prolonged PEX and death, caplacizumab be given systematically, as a first line 
therapy in addition to PEX, corticosteroids and rituximab. A registry of every case 
treated with caplacizumab and further evaluation are warranted to confirm or not the 
potential benefit of this drug in combination with other first line therapies.  
The best standard of care of ICU management should be provided, including 
deep vein thrombosis and peptic ulcer prophylaxis, as well as limited use of red cells 
transfusions10. Folate replacement should be administered over the first two weeks98. 
Anti-platelet therapy are quite broadly used in patients with severe cardiac or brain 
involvement, and once platelet count reaches 50G/l. However, evidence supporting 
such practice remains poor 103. Moreover, the use of caplacizumab raises concerns for 
its combination with anti-platelet agents. However, trials assessing the efficacy of 
caplacizumab did not recommend to withdraw anti-platelet agents, even though we 
cannot assess whether the combination of the two was associated with increased 
bleeding rates17,103. Attention should be paid to prevent and monitor the dialysis catheter 
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for thrombosis or infection, to maintain adequate blood pressure control, and to provide 
prophylaxis against herpes simplex virus and Pneumocystis jirovecii in case of 
protracted corticosteroid requirement. Experts suggest that prophylactic antibiotics 
should not be administered. As stated before, platelet transfusion should be avoided as 
it may worsen microvascular injury and should be limited to severe bleeding (i.e., 
cerebral haemorrhage, etc...) 56,96. 
To optimize efficacy, every treatment should be given after PEX, and 
therapeutic drug monitoring should be adjusted where appropriate.  
Daily blood cell count, troponin level and haemolytic activity should be 
performed. These experts also recommend to perform an ECG every day. ADAMTS13 
activity and anti-ADAMTS13 inhibitors should be assessed every week until remission, 
then every two weeks for one month, then monthly for three months. Low ADAMTS13 
activity identifies a group of patients at high risk of unresponsiveness to treatment or 
relapse 11,104,105 106. This can occur despite the use of rituximab and/or 
caplacizumab17,90,104,107. Last, standard of care should also include usual measures to 
prevent, diagnose and treat infections in immunocompromised patients. 
 
Recommendations for a standard of care for patients with severe TTP (Table 7C) 
a) Therapeutic plasma exchanges 
1. TPE must be preferred to plasma infusions in TTP patients. Plasma 
infusions must be reserved when TPE is not immediately available.  
GRADE: 1+, Agreement: Strong 
2. Experts suggest to perform one TPE per day with a dose of plasma of 
60 ml/kg (1.5 x blood mass) until platelet count>150G/L for ≥48 hours. 
GRADE: Expert opinion, Agreement: Strong 
3. Experts suggest that TPE should be initiated within 6 hours of diagnosis. 
GRADE: Expert opinion, Agreement: Strong 
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4. If TPE is not available, patients should probably be transferred to 
another centre where TPE is available. 
GRADE: 2+, Agreement: Strong 
b) Steroids 
1. Prednisone or methylprednisolone should probably be administered in 
association to TPE in TTP patients.  
GRADE: 2+, Agreement: Strong 
2. Experts suggest a dose of 1 mg/kg/d for 21 days.  
GRADE: Expert opinion, Agreement: Strong 
3. Experts suggest that in case of severe TTP, high dose pulse steroids (1 
g of methylprednisolone) can be given for three consecutive days. 
GRADE: Expert opinion, Agreement: Strong 
 
c) Monoclonal antibodies 
1. Rituximab must be used in patients with relapsing autoimmune TTP. 
GRADE: 1+, Agreement: Strong 
2. Rituximab should probably be used as a first line therapy in severe TTP 
GRADE: 2+, Agreement: Strong 
3. Experts do not advocate nor discourage first-line rituximab in all TTP 
patients.  
GRADE: Expert opinion, Agreement: Strong 
4. Caplacizumab must be used as a first line therapy in severe TTP 
GRADE: 1+, Agreement: Strong 
 
 
d) Supportive care 
1. Experts suggest folate supplementation, prophylactic anticoagulation 
and antiplatelet agents as soon as platelet count reaches 50G/L, monitoring of the 
central venous catheter for thrombosis or infection, tight blood pressure control, 
gastro-duodenal ulcer prophylaxis, prophylaxis against HSV and Pneumocystis 
jirovecii in case of protracted corticosteroids requirement. 
GRADE: Expert opinion, Agreement: Strong 
2. Experts suggest that prophylactic antibiotics should not be 
administered  
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GRADE: Expert opinion, Agreement: Strong 
3. Platelet transfusion should probably be avoided in TTP patients and 
be restricted to severe bleeding (i.e., cerebral haemorrhage, etc...). 
GRADE: Expert opinion, Agreement: Strong 
 
 
Recommendations for a second line therapy in patients with severe TTP (Table 7C) 
Clinical remission is defined by a haematological response, resolution of 
haemolysis and resolution of organ dysfunction. Haematological response is defined by 
the normalization of platelet count (>150G/L for 2 consecutive days). In case of bone 
marrow dysfunction, return to baseline platelet count is required. Haemolysis should be 
unapparent despite TPE interruption. Lastly, improvement in cardiac, renal and 
neurologic functions can be rapid, even though in the most severe cases recovery can 
be delayed with persistent or residual organ impairment reported 35,39,49,108.  
Unresponsive or refractory TTP can be defined by persistent thrombocytopenia 
and haemolysis after at least 7 days of standard treatment 40,94. In practice, the lack of 
platelet normalization by day 5 associated with persistent signs of haemolysis (LDH 
level) and/or severe cardiac or neurological manifestations defines a group of patients 
at high risk of poor outcomes and who need treatment intensification94. Kidney 
involvement may take longer to recover, especially in patients requiring renal 
replacement therapy39. It is known that surgery, extracorporeal circulation, transfusions 
or sepsis can generate high shear stress rates from the release of ultra large VWF 
multimers and may trigger TTP exacerbations 70.  
Disease exacerbation or TTP flare refers to a recurrence of thrombocytopenia 
and other TTP manifestations either during TPE or within 30 days after stopping TPE, 
whereas TTP relapse refers to TTP recurrence later than 30 days after TPE therapy has 
been completed94. 
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Immunologic response is however not based on clinical findings or standard 
biology. It is defined by the recovery of normal ADAMTS13 activity and complete 
clearance of anti-ADAMTS13 antibodies 9,27,104,105. 
Patients in clinical and haematological remission may still have a low 
ADAMTS13 activity and therefore a high risk of relapse. These patients require careful 
monitoring and prolonged rituximab administration until ADAMTS13 activity recovers 
and remains stable over time104,107. Caplacizumab may have a special role in these 
patients with persistent high risk of thromboembolic events for a longer time, at least 
until ADAMTS13 becomes detectable again. 
Triggers for exacerbation (most particularly infection, thrombosis and error in 
treatment delivery) must be looked for and treated 70. A personalized approach must be 
given priority. No study has properly evaluated therapeutic strategies for TTP 
exacerbation or for patients who are unresponsive to a first line therapy that includes 
TPE and corticosteroids85. 
If patients did not receive caplacizumab and rituximab in addition to PEX and 
corticosteroids, the two may be added in combination with twice-daily PEX110,111, and 
intensification of immunosuppression with higher dose or pulse corticosteroids100. 
Rituximab onset of action is delayed and can be expected by day 7-10 at best75. If 
patients received first line caplacizumab and rituximab in addition to PEX and steroids, 
twice-daily PEX and high dose corticosteroid pulses should be started. According to 
the clinical severity, vincristine or cyclophosphamide may be added. Vincristine has 
provided fast, effective and sustained clinical and biological responses84,112, and 
cyclophosphamide has been used with success74,83,113. Other drugs such as bortezomib, 
cyclosporine, mycophenolate mofetil, N-Acetylcysteine, eculizumab, daratumumab or 
immunoadsorption have been more rarely used. The choice of a second line therapy 
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depends on the type of underlying condition, if any (pregnancy, AIDS, systemic 
rheumatic disease…). As stated above, we suggest caplacizumab as a first line agent in 
all severe TTP patients, especially with a high and prolonged risk of thromboembolic 
events and sudden death17,103. In case of failure of rituximab, ofatumumab might be an 
option109. It has also been suggested that in patients unresponsive to treatment, 
centrifugation devices might be preferred over plasma filters (lower shear stress rates). 
Finally, salvage splenectomy remains an alternative for those patients who 
either show no clinical and biological response to all of the previous strategies, and/or 
have a clinical emergency based on cardiac or neurological thromboembolic 
events83,85,114,115. Splenectomy may be beneficial and hamper the autoimmune process 
by eliminating helper-T-cells, however this procedure should be a last resort treatment 
after failure of first and second line therapies.  
For all TTP patients, advice should be obtained from a TTP specialist. More 
particularly, in unresponsive cases, the second-line therapy should be discussed with 
TTP specialists, including biologists and immunologists.  
 
Recommendations for second line therapy in TTP patients (table 7D) 
1. Experts suggest that the lack of platelet normalization by day 5 
associated with persistent signs of haemolysis (LDH level) and/or severe cardiac or 
neurological manifestations define unresponsive or refractory TTP. The Kidney 
involvement may take longer to recover, especially in patients requiring renal 
replacement therapy. 
GRADE: Expert opinion, agreement: Strong 
2. Experts suggest that if patients did not receive caplacizumab and 
rituximab in addition to TPE and steroids, the two medications must then be added. 
GRADE: Expert opinion, agreement: Strong 
3. Experts suggest that if patients did receive first-line caplacizumab and 
rituximab in addition to TPE and steroids, twice-daily TPE and high dose steroid 
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pulses should be started. According to the clinical severity, vincristine or 
cyclophosphamide can be added. 
GRADE: Expert opinion, agreement: Strong 
4. Experts suggest that the choice for the second line therapy depends on 
the type of underlying condition, if any (pregnancy, AIDS, systemic rheumatic 
disease…). 
GRADE: Expert opinion, agreement: Strong 
5. Experts suggest that splenectomy should probably remain an 
alternative therapy for unresponsive TTP; however, with appropriate and timely TTP 
management it should be reserved as a salvage therapy.  
GRADE: Expert opinion, agreement: Strong 
6. Experts suggest that for all TTP patients, an advice should be sought 
from a TTP specialist. More particularly, in unresponsive cases, the second-line 
therapy should be discussed with a TTP specialist. 
GRADE: Expert opinion, agreement: Strong 
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Unanswered clinical questions – and research agenda about TTP in the ICU 
Despite improvements in our understanding of TTP pathophysiology, the 
advent of new therapeutic agents, and optimal ICU management, there are still specific 
needs and unanswered clinical questions when caring for TTP patients.  
 
Initial TTP management 
- Can deep learning allow to identify variables that predict ADAMTS13 activity 
and inhibitor testing with a close-to 100% sensitivity? 
- Would the use of clinical algorithms and artificial intelligence application 
improve TTP recognition, and exclude alternate diagnosis? 
- Would the use of therapeutic algorithms translate into better outcomes? 
- Are there risk-stratification models that would allow early ICU discharge in 
patients at low risk of clinical deterioration (delta-platelet rate? troponin?)? 
- Should we standardize the definition of severe TTP and suggest tailored standard 
of care for these specific patients?  
 
At the onset of TTP treatment  
- We have advocated for a full quadruple initial therapy combining upfront PEX, 
corticosteroids, rituximab and caplacizumab for all patients. An ideal goal would 
be to prevent early deaths, and limit the number of severe thromboembolic events. 
We realize that some patients will be cured with corticosteroids only64, some with 
PEX andcorticosteroids70, and others with adding rituximab75,77. Patients 
unresponsive to PEX and corticosteroids represent a substantial subgroup of 
patients that could be identified early after ICU admission40. Whether the full 
quadruple therapy should be limited to those patients with cardiac and 
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neurological involvement, or those with low platelet count at day 2, remains an 
unresolved question and deserves to be addressed in another trial. For that to be 
done, updating factors associated with mortality in the era of comprehensive 
management of TTP patients is required.  
- What is the optimal level of cardiac and neurologic monitoring? 
- Should we develop a patient’s leaflet mentioning all the risk encountered in TTP, 
particularly the risk of bleeding with caplacizumab? Guidelines for specific 
monitoring of von Willebrand factor ristocetin cofactor activity (vWf:RiCo) ratio 
could be provided and disseminated. 
- What is the role of anti-platelet therapy in TTP patients receiving caplacizumab? 
Should it be administered to all patients or to those with severe neurologic or 
cardiac involvement?  
- Should we consider adjuvant therapy with minor side effects for every patient 
with the hope that it will ultimately allow to reduce the number of days requiring 
TPE (N-acetylcystein, magnesium sulfate, etc.) 
 
Specific questions regarding TTP treatments  
- Access to TPE depends on countries, hospitals and uses. However, studies have 
never controlled for factors such as devices (centrifuge-based systems vs. plasma 
filters), anticoagulation (citrate versus heparin) or plasma volume that vary from 
one study to another. 
- What is the best regimen for corticosteroids and rituximab in TTP? Some experts 
recommend of routine pulse corticosteroids for three days followed by 1mg/kg of 
methylprednisolone, others recommend rituximab in doses and timing depending 
on B-cell data.  
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- Should second line therapy be standardized? In patients not receiving initial 
rituximab and caplacizumab, second line therapy should include these two drugs, 
possibly associated with pulse corticosteroids and twice-daily TPE. However, 
what would be the standard therapy in patients unresponsive to total therapy? If 
these patients are clinically stable, treatments such as vincristine, 
cyclophosphamide, and cyclosporine may be initiated. However, if they are 
sicker, strategies that can provide faster resolution should be considered. 
- In patients who are unresponsive to total therapy and severe thromboembolic 
events, should splenectomy be considered as a second line therapy? There is no 
doubt that this clinical vignette embodies patients at very high risk of early death. 
In that case, splenectomy would still remain limited to a small number of patients, 
but may allow faster recovery in these very high risk patients.  
- In patients unresponsive to therapy, should proactive strategies to clear anti-
ADAMTS13 inhibitors be attempted (immunoadsorption, new membranes to 
clear antibodies etc.)?  
 
Questions about specific organ involvement and treatments 
- Should patients with severe cardiac involvement (ST elevation, high troponin) 
and cardiovascular risk factors routinely undergo cardiac catheterization, 
angioplasty and stenting if appropriate? 
- Should we consider specific management in patients with cerebral deterioration? 
Fibrinolytic therapy in large stroke, specific monitoring of cerebral edema and 
seizure in patients with coma, specific drugs in status epilepticus?  
- Should we tailor red cell transfusion thresholds to myocardial and neurological 
involvement? 
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- Can we still ascribe organ dysfunction to TTP when ADAMTS13 levels have 
reached a certain level? Should ADAMTS13 concentrations be the main criteria 
for discontinuing plasma therapy, rituximab and caplacizumab? 
- What are the long term outcomes of neurologic and cardiac involvement? What 
are the actual rates of cognitive disorders one year after ICU discharge? 
Depression rates? Cardiac insufficiency rates?  
- In the years to come, will caplacizumab be changing the standard of care? (TPE 
intensity, ICU admission, intensity of immunosuppression)?  
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Conclusion 
TTP is a life threatening disease that benefited from significant diagnostic and 
therapeutic advances over the last decade. A standardized management protocol allows 
to both optimizing initial care and avert morbidity and mortality, and also to 
strengthening the impact of new therapeutic strategies such as rituximab and 
caplazimuab. Large ICU registries are needed to validate reliable clinical and biological 
markers that allow to stratify TTP patients at high risk of initial cardiovascular and 
neurological complications, but also to recognize low acuity TTP patients in whom 
management could be rapidly be de-escalated or even streamlined.   
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Figure 1: Clinical features and signs in acute TTP: Symptoms in red are the most frequent whereas symptoms in blue are the most severe.  
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Figure 2: Assessing TTP severity 
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Figure 3. TTP pathophysiology and therapeutic targets. (A) In physiologic conditions, 
ultralarge vWF multimers that are hyperadhesive to platelets are cleaved by ADAMTS13 to 
smaller, less adhesive multimers. (B) In TTP, low ADAMTS13 activity (often caused by auto-
antibody inhibition) facilitates spontaneous binding of ultralarge vWF multimers to platelets, 
promoting aggregation, platelet consumption and microthrombi formation within the capillary 
microvessels. (C) The treatment is based on removal of auto-antibodies and replacement of 
ADAMTS13 by plasma exchange and immunomodulation. Corticosteroids are recommended 
in the initial phase together with TPE, whereas other additional immunomodulatory strategies 
are optional. Inhibition of the interaction between ultralarge vWF multimers and platelets by 
caplacizumab is becoming approved.  
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Figure 4: Diagnostic workup in patients with thrombotic microangiopathy syndromes 
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ADAMTS13 activity < 10% 
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ADAMTS13 gene mutation  
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Diagnosis of TMA: MAHA and peripheral thrombocytopenia 
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Table 1: Clinical criteria and scoring systems for diagnosing ADAMTS-13 deficiency 
 
Clinical criteria to predict ADAMTS13 deficiency. Coppo et al. 2010 1  
Creatinine < 200 μmol/L  
Platelet count< 30 x 109/L  
Positive Antinuclear antibodies  
Three criteria predict severe ADAMTS13 deficiency with a 98% 
(94-100) specificity, 47% (41-53) sensitivity, 99% (96-100) 
positive and 39% (36 – 42) negative predictive values 
 
Point-based ADAMTS13 deficiency prediction score. Bentley et al. 2010 2,3 
 
Creatinine > 2.0 mg/dL  
Platelets > 35 x 109/L  
D-dimer > 4.0 µg/ml  
Reticulocyte >3%  
Indirect bilirubin > 1.5 µg/ml  
Points  
-11.5  
-30  
-10  
+21  
+20.5  
 
A score>30 points corresponds to a 100 % probability 
of severe ADAMTS13 deficiency 
A score between 20 and 30 points corresponds to a 
40% probability of severe ADAMTS13 deficiency 
A score below 20 points corresponds to a 0% 
probability of severe ADAMTS13 deficiency 
The PLASMIC score. Bendapudi et et al. 2016 4  
 
Platelet count< 30 x 109/L  
Combined hemolysis variables*  
Absence of active neoplasia  
Absence of transplant 
MCV < 9 x 10-14  L  
INR > 1.5  
Creatinine < 2.0 mg/dL  
Points  
1  
1  
1  
1 
1  
1  
1  
 
 
A score ≤4 corresponds to a low risk for severe 
ADAMTS13 deficiency 
A score of 5 corresponds to an intermediate risk for 
severe ADAMTS13 deficiency  
A score of 6 or 7 corresponds to a high risk (>80%) 
for severe ADAMTS13 deficiency. Patients with 
confirmed TTP had a median score of 7 (IQR 6–7). 
* Combined hemolysis variables are defined as reticulocyte count >2-5%, undetectable haptoglobin, or 
indirect bilirubin >2.0 mg/dl 
MCV: Mean corpuscular value; INR: international normalized ratio 
TTP: thrombotic thrombocytopenic purpura 
 
References for table 1:  
1 Coppo P, Schwarzinger M, Buffet M, et al. Predictive features of severe acquired ADAMTS13 deficiency in idiopathic 
thrombotic microangiopathies: the French TMA reference center experience. PloS One 2010; 5: e10208. 
2 Bentley MJ, Wilson AR, Rodgers GM. Performance of a clinical prediction score for thrombotic thrombocytopenic 
purpura in an independent cohort. Vox Sang 2013; 105: 313–8. 
3 Bentley MJ, Lehman CM, Blaylock RC, Wilson AR, Rodgers GM. The utility of patient characteristics in predicting 
severe ADAMTS13 deficiency and response to plasma exchange. Transfusion (Paris) 2010; 50: 1654–64. 
4 Bendapudi PK, Hurwitz S, Fry A, et al. Derivation and external validation of the PLASMIC score for rapid assessment of 
adults with thrombotic microangiopathies: a cohort study. Lancet Haematol 2017; 4: e157–64. 
Table 2: Studies reporting on critically ill patients with TTP  
 Zafrani Mariotte Darmon  Pene Gasparovic Knobl  
Country France, single centre France, single centre France, single centre France, multicentre  Croatia Austria, single centre 
Study type Retrospective  Prospective registry   Retrospective  Retrospective  Retrospective  Retrospective  
Period 2001 – 2013  1997 – 2011 2000 – 2003  1998 – 2001 Not reported 1992 – 1995  
Population ICU patients with TTP  ICU patients with TTP ICU patients with TMA ICU patients with TMA ICU patients with TTP ICU patients with TTP 
N patients 92 86 36 63 (21 with TTP) 18 6 
Severity  SOFA 6.5 (IQR 5-9)a  SAPSII 27 (IQR 13-42) SAPS II 45±26 - - 
CNS 
dysfunction 
86.9% 79% 50% Mean Glasgow Coma 
scale (GCS) 12 
88.8% Mild 42%d 
Severe 58%e 
Renal 
impairment 
Stage 1/2: 10-26% b 
Stage 3: 27.2% 
64% Creatinine Clearance 
<60mL/min in 55.4% 
Creatinine >250 μmol/l 
in 48%  
38.8% 42% 
Cardiac 
involvement 
Hypotension: 15.2% 
Cardiac signs: 50% 
Chest pain/ CHF: 36% 
Shock: 5% 
Shock: 8.3% - - - 
Other 
clinical 
features 
Digestive signs: 40.2% 
Fever: 21.7% 
 
Digestive signs: 38% 
Fever: 30%; Bleeding: 
24%; Thrombosis: 12% 
- - - Fever: 50% 
 
Organ 
support 
RRT: 15.2% - Mechanical ventilation: 
30.5%, dialysis: 19.4% 
Vasopressors: 8.3% 
- - Mechanical 
ventilation: 50% 
dialysis: 0% 
Prognostic 
factors 
Risk of AKI: OR 3.85 
per 0.25 unit decrease 
in C3 levels  
All deaths were in a 
group of patients with 
”unresponsive” TTPc  
Hospital mortality: 
IMV (OR 8.3) 
LOD (OR 1.4/point) 
GCS: HR 0.85; Plasma 
exchange: HR 0.27 
- - 
ICU/Hospital 
mortality 
- / 4.3% 8.1% / 10.5% 19.4% / 19.4% 34.9% / 34.9% - / 5.6% 16.7% / 33.3% 
Thrombotic microangiopathy (TMA); Creatinine clearance (CrCl); Congestive heart failure (CHF); invasive mechanical ventilation (IMV); renal replacement 
therapy (RRT); acute kidney injury (AKI); plasma exchange (PEX). aDay 1 SOFA score. bDefined as per KDIGO 2012 guidelines; cDefined as use of second line 
treatment, >15 PEXs or death due to uncontrolled active TTP. dDizziness, headaches, dysesthesia, vertigo, fatigue or dysphasia. eVision loss, paresis, seizures or coma. 
LOD: logistic organ dysfunctions score 
Table 3: Registry based studies describing TTP population 
Author Mariotte (2016) Hovinga (2010) Coppo (2010) Scully (2008) 
Registry French national registry for TMA Oklahoma TTP registry French TMA reference center South East England TTP registry 
Years 1999 – 2013  1989 – 2008  2000 – 2007  2002 – 2006  
Number of patients 772 376 (60 patients with measured 
ADAMTS13 deficiency) 
214 176 
Age at presentation 43 years ADAMTS13 <10%: 41 years 
ADAMTS13 ≥10%: 51 years 
ADAMTS13 deficient: 39 years 
ADAMTS13 detectable: 51 years 
42 years 
Females 68% ADAMTS13 <10%: 82% 
ADAMTS13 ≥10%: 63% 
75% 75% 
Idiopathic TTP 49% 39% - 77% 
Pregnancy-related 
TTP 
8% 7% - 2% 
Congenital TTP 3% - - 5% 
Neurological features 61% 
(Headache or confusion 30%) 
(Severe symptoms 31%) 
ADAMTS13 <10%: 50% 
ADAMTS13 ≥10%: 44% 
Focal deficit 23% 
Headache 21%; Coma 21%; 
Confusion 18%; Seizure 12%;  
78% 
(including 10% with coma) 
Cardiac involvement - - - 42% 
Renal impairment 40% ADAMTS13 <10%: 10% 
ADAMTS13 ≥10%: 54% 
End stage renal disease 5% 33% 
Other symptoms Fever 40% 
Digestive symptoms 35% 
- - Digestive symptoms 35% 
 
 
Table 4: differential diagnoses of thrombocytopenia with microangiopathic hemolytic anemia during pregnancy 
 
 ASSOCIATED WITH PREGNANCY CAUSED BY PREGNANCY 
 TTP Atypical-
(complement 
mediated)-HUS 
Idiopathic 
thrombocytopenia 
purpura 
HELLP DIC Acute fatty liver 
of pregnancy 
Timing Trimesters 1-3 
post partum 
Trimesters 1-3 
post partum ++ 
Trimesters 1-3 
post partum 
>20 weeks,  
post partum 
Trimesters 2 & 3 Trimester 3 
Platelets (/microL) Typically <30,000 Typically <100,000 <50,000 50,000-100,000 Mild drop Mild drop 
Schistocytes +++ +++ - - / + - / + - 
Additional 
hematologic changes 
MAHA 
high LDH 
low haptoglobin 
MAHA 
high LDH 
low haptoglobin 
No MAHA 
high LDH 
low haptoglobin 
Prolonged PT & aPTT 
Low fibrinogen (overt 
DIC) 
Possible prolonged 
PT & aPTT 
low fibrinogen 
DIC No No No In 10% of cases +++ 
Beware of normal 
fibrinogen in setting of 
inflammation 
No 
ADAMTS13 Activity <10% ≥ 10%-normal ≥ 10%-normal ≥ 10%-normal ≥ 10%-normal ≥ 10%-normal 
Hepatic Changes None or mild 
elevation in enzymes 
No No Elevated liver 
enzymes** 
Possible  Markedly abnormal 
liver enzymes, liver 
synthetic dysfunction 
Renal Changes Mild Severe No None-Mild Possible ATN Possible 
Neurologic Changes Often present*** Rare No Pre-eclampsia+++ Possible  Encephalopathy 
Other Features 
 
Elevated troponin  
Unresponsive TMA 
that may worsen after 
delivery 
Unresponsive TMA that 
may worsen after 
delivery 
/ 80-85% have 
concurrent 
preeclampsia 
Presence of a trigger (i.e.: 
amniotic fluid embolism, 
fetal demise, PPH) 
Hypoglycemia, 
Potential multisystem 
organ failure 
Management Plasma therapy; 
immunosuppression 
Anti-complement therapy 
(Eculizumab) 
Glucocorticoids IVIG 
immunosuppression 
Delivery Treat underlying cause; 
Supportive care with 
blood products  
Delivery, Early 
involvement of liver 
transplant team 
Delivery Not curative;  
Only indicated for 
fetal issues 
Not curative;  
Only indicated for fetal 
issues 
Not curative Curative 
Timing 
determined by OB 
and ICU  
Curative if HELLP 
related DIC or fetal 
demise 
Curative 
 May need transplant 
*Pregnancy may unmask these conditions  
** Liver enzymes might be markedly elevated in severe cases of intrahepatic hemorrhage, subcapsular hematoma or hepatic infarcts. 
*** Stroke, seizures, weakness, aphasia, mental status changes etc. AFLP Acute fatty liver of pregnancy; ATN Acute tubular necrosis; cTMA complement mediated 
thrombotic microangiopathy; DIC Disseminated intravascular coagulopathy; HELLP Hemolytic anemia, Elevated Liver enzymes, Low Platelets; LDH Lactate 
dehydrogenase; ITP Idiopathic thrombocytopenia purpura; MAHA microangiopathic hematologic anemia; PT, aPTT prothrombin and activated partial 
prothrombin time; TTP Thrombotic thrombocytopenic purpura 
 
As a reminder, other conditions of severe thrombocytopenia in pregnancy that are not pregnancy-related include antiphospholipid antibody syndrome, systemic lupus 
erythematosus, drug induced thrombocytopenia, sepsis, and malignancy.  
 
Table 5. Manifestations of severe organ dysfunction in TTP 
 
 
CNS In brain MRI acute changes are often seen; most 
commonly PRES. 
Symptoms of brain ischemia (severe seizures, 
coma) have been associated to severe 
ADAMTS13 deficiency but might be encountered 
in other TMA syndromes including STEC-HUS 
and complement-mediated HUS. 
Brain hemorrhage is associated with decreased 
survival and altered functional outcomes. 
Worrisome clinical status and brain imaging need 
to be interpreted with caution as complete 
neurological recovery has been reported. 
 
De Marinis 18 
Burrus 19 
Heart Heart involvement is frequent and probably under-
diagnosed in TTP. The triad chest pain/ECG 
changes/increased troponin must be routinely 
sought. Echocardiography alterations must be 
routinely excluded.  
Severe myocardial involvement with arrhythmias, 
severe myocardial infarction, cardiogenic shock, 
cardiac arrest, Takotsubo cardiomyopathy rarely 
occurs but is responsible for early deaths.  
 
Benhamou 2015 6 
Balasubramaniyam 
2013 20 
Fourmont 2018 
Kidneys Development of acute kidney injury is common 
and renal replacement therapy might be required. 
Long term renal outcome might be altered in 
severe TTP patients, and in those with previous 
renal insufficiency or other comorbidities.  
 
Zafrani 2015 23 
GI-tract Acute pancreatitis and severe gastrointestinal 
bleeding have been reported. Abdominal pain 
should not be mixed up with cardiac angina.  
 
Hosler 2003 21 
Yamamura 1998 22 
Other 
Severe 
organ 
involvement 
Adrenal glands, liver, retina, skin … Hosler 2003 21 
Yamamura 1998 22 
 
 
Abbreviations: ADAMTS13: A Disintegrin And Metalloproteinase with a ThromboSpondin 
type 1 motif, member 13, MRI: magnetic resonance imaging, PRES: posterior reversible 
encephalopathy syndrome, TTP: thrombotic thrombocytopenic purpura. 
 
 
Table 6. Factors associated with worse outcome in TTP patients 
 
Variable                                        Nature of the association                           Reference 
1. Age Increasing age is associated with increasingly bad prognosis.  
This is especially true in the age group > 60 years. 
Goel 2016 10 
Chaturvedi 2013 7 
Benhamou 2012 8 
2. Increased 
cardiac troponin 
level 
Increased serum troponin I is associated with increased 
treatment refractoriness and mortality; monitoring is crucial 
and could maintain a high level of suspicion for myocardial 
ischemia and identify patients with a higher risk of early death. 
Brazelton 2016 5 
Benhamou 2015 6 
3. Cerebral 
involvement 
Unlike headaches, symptoms such as stupor, seizures and 
coma are associated with poor outcomes. Although TTP is a 
thrombotic disease, cerebral bleeding may occur and impacts 
survival as well as functional outcomes. 
Chaturvedi 2013 7 
Benhamou 2012 8 
Rose 1987 9 
4. Delayed 
diagnosis  
Failing to recognize TMA syndrome, to perform complete 
clinical and biological diagnostic workup, and to obtain 
ADAMTS13 to ascertain TTP is associated with adverse 
outcomes. For instance, clinicians must be aware that 
schistocytes might not be seen initially, that in rare situations 
DAT could be positive, or that reticulocytes might be delayed.  
Grall 2017 11 
5. Platelet 
transfusions 
Platelet transfusions are associated with clinical deterioration 
and increased relapse rate. Delayed diagnosis increases the risk 
of platelet transfusions 12,13  
Benhamou12 
Yoshii 13 
6. Increased LDH An increased LDH at admission, as well as persistent LDH 
elevation after two plasma exchanges, are associated with 
worse outcomes. 
Chaturvedi 2013 7 
Benhamou 2012 8 
7. Unresponsive/ 
refractory TTP 
Lack of response to plasma exchange and steroids, and need 
for a second line therapy are associated with worse outcomes. 
Age >60y, neurological or cardiac manifestations at diagnosis, 
and day 2 platelet count <15.109/L have been associated with 
unresponsive TTP. 
Mariotte 2013 14 
 
8. Acute disease 
vs. relapse 
Recurrent episodes of TTP are usually less severe than the first 
acute episode, however should always be regarded as a 
potentially fatal condition. 
Veyradier 2016 15 
Lotta 2010 16 
9. Ethnicity Patients from Black African or Caribbean origins are at highest 
risk for TTP, but may have better outcome than white patients 
with TTP. Underlying systemic disease always needs to be 
diagnosed and treated.  
Martino 2016 17 
10. Other factors  Cardiac arrest; Pancreatitis; HIV infection;  
Comorbid conditions beyond age 
 
 
Abbreviations: DAT: Direct anti-globulin test (Coomb’s test), LDH: lactate dehydrogenase, TTP: 
thrombotic thrombocytopenic purpura. 
 
 
Table 3.A. GRADES for the TTP diagnostic workup 
 GRADE Ref 
A. Diagnostic workup 
a) Experts suggest that all patients suspected of having TTP should undergo, at least, the following workup  
• Full clinical screening for organ injury (neurologic, cardiac, renal, gastrointestinal). 
• Biological workup to diagnose TMA: Blood cell count and smear (reticulocytes and schistocytes). Biochemistry: LDH, haptoglobin, 
bilirubin, Direct Antiglobulin Test to rule out Evans syndrome, basic coagulation tests to rule out DIC, proteinuria, haematuria.  
• Biological workup to confirm TTP: Non-heparinised samples for ADAMTS13 activity and anti-ADAMTS13 antibodies before TPE, 
alternative pathway of the complement system study, and PCR on rectal swab for shiga-toxin.  
• Minimal tests to assess organ involvement (troponin, ECG, renal function, lipase) and to identify possible associated conditions 
(auto-immunity markers, HIV serology, β-HCG, blood cultures). 
• Cross-matching before transfusion (blood group, hepatitis serologies). 
Expert 
Opinion 
 
b) Blood samples should probably be obtained before starting plasma therapy. 2+ [1, 2] 
[3] 
c) Diagnostic workup should probably not delay TPE. 2-  
d) When ADAMTS13 activity cannot be easily or quickly measured, diagnostic scores (French score, Bentley score, PLASMIC score) 
should probably be used to assess whether ADAMTS13 is likely to be undetectable. 
2+ [4] 
[5, 6] 
[7–10] 
 
 
  
Table 3.B. GRADES for the assessment of TTP severity  
 GRADE Ref 
B. Assessment of patient’s severity 
a) Organ dysfunction should probably be assessed routinely at presentation and throughout the course of TTP. 2+ [11–14] 
b) Experts do not provide guidance for the management of organ dysfunction in TTP patients.  Not graded  
c) Experts suggest that the presence of cardiac involvement (ie. chest pain, ECG and trans-thoracic echography changes, and 
troponin) must be assessed routinely at presentation and on a regular basis throughout the course of TTP.  
Expert 
opinion 
[6, 11, 
11, 12, 
14–18] 
d) Older age, cerebral involvement and persistently high LDH may help identify TTP patients at increased risk of early death.  2+ [11] 
e) Experts suggest that all patients diagnosed with TTP must be initially admitted to an area of Critical Care in order to monitor 
and manage organ dysfunctions, and to provide urgent plasma exchange therapy.  
Expert 
opinion 
[16, 19] 
 
 
f) Experts suggest that ICU discharge be allowed when TPE can be tapered or stopped, when signs of haemolysis disappear and 
platelet count increases over 150G/L, which usually correlates with cardiac and neurological improvements.  
Patients can be discharged from the ICU earlier if there is a TPE unit in the hospital. 
Expert 
opinion 
[16, 19] 
 
 
  
Table 3.C. GRADES for the standard of care for ICU patients with TTP 
 GRADE Ref 
C. Standard of care in adult patients with a suspicion of TTP 
a) Therapeutic Plasma Exchange (TPE) 
1. TPE must be preferred to plasma infusions in TTP patients. Plasma infusions must be reserved when TPE is not immediately 
available.  
1+ [4]  
[20, 21] 
[12, 16] 2. Experts suggest to perform one TPE per day with a dose of plasma of 60 ml/kg (1.5 x blood mass) until platelet count>150G/L 
for ≥48 hours. 
 
Expert 
opinion 
3. Experts suggest that TPE should be initiated within 6 hours of diagnosis. 
 
Expert 
opinion 
4. If TPE is not available, patients should probably be transferred to another centre. 
 
2+ 
 
b) Steroids 
1. Prednisone or methylprednisolone should probably be administered in association to TPE in TTP patients.  
 
2+ [14, 18] 
[22] 
[23] 2. Experts suggest a dose of 1 mg/kg/d for 21 days.  
 
Expert 
opinion 
3. Experts suggest that in case of severe TTP, high dose pulse steroids (1 g of methylprednisolone) can be given for three 
consecutive days. 
 
Expert 
opinion 
c) Monoclonal antibodies  
1. Rituximab must be used in patients with relapsing autoimmune TTP. 
 
1+ [24–27] 
2. Rituximab should probably be used as a first line therapy in severe TTP. 
 
2+ 
3. Experts do not advocate nor discourage first-line rituximab in all TTP patients.  
 
Expert 
opinion 
4. Caplacizumab must be used as a first line therapy in severe TTP. 
 
1+  
d) Supportive care 
1. Experts suggest folate supplementation, prophylactic anticoagulation and antiplatelet agents as soon as platelet count reaches 
50G/L, monitoring of the central venous catheter for thrombosis or infection, tight blood pressure control, gastro-duodenal 
ulcer prophylaxis, prophylaxis against HSV and Pneumocystis jirovecii in case of protracted corticosteroids requirement. 
Expert 
opinion 
[28] 
2. Experts suggest that prophylactic antibiotics should not be administered  
 
Expert 
opinion 
3. Platelet transfusion should probably be avoided in TTP patients and be restricted to severe bleeding (i.e., cerebral haemorrhage, 
etc...). 
 
2- 
  
 
Table 3.D. GRADES for the selection of a second-line therapy in TTP patients 
 GRADE Ref 
D. Second line therapy 
1. Experts suggest that the lack of platelet normalization by day 5 associated with persistent signs of haemolysis (LDH level) and/or 
severe cardiac or neurological manifestations defines unresponsive or refractory TTP. The Kidney involvement may take longer 
to recover, especially in patients requiring renal replacement therapy. 
 
Expert 
opinion 
[29] 
 
2. Experts suggest that if patients did not receive caplacizumab and rituximab in addition to TPE and steroids, the two medications 
must then be added. 
 
Expert 
opinion 
[21, 30, 
31] 
 
3. Experts suggest that if patients did receive first-line caplacizumab and rituximab in addition to TPE and steroids, twice-daily TPE 
and high dose steroid pulses should be started. According to the clinical severity, vincristine or cyclophosphamide can be added. 
 
Expert 
opinion 
[24–26, 
32] 
 
4. Experts suggest that the choice for the second line therapy depends on the type of underlying condition, if any (pregnancy, AIDS, 
systemic rheumatic disease…). 
 
Expert 
opinion 
[23, 
33–35] 
 
5. Experts suggest that splenectomy should probably remain an alternative therapy for unresponsive TTP, however, with 
appropriate and timely TTP management it should be reserved as a salvage therapy.  
 
Expert 
opinion 
[36–38] 
 
6. Experts suggest that for all TTP patients, an advice should be sought from a TTP specialist. More particularly, in unresponsive 
cases, the second-line therapy should be discussed with a TTP specialist. 
 
Expert 
opinion 
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